Physician profile
Scott E Segal
NPI 1154373942
$2,643.36
in general payments reported to CMS, 2019-2025
21 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $184 · 2021: $299 · 2022: $564 · 2023: $810 · 2024: $85.98 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $486.25 | 2019-2023 | Wavelight Refractive Suite, Clareon, Wavelight Ex500 Excimer Laser |
| Abbvie INC. | $460.47 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $366.89 | 2019-2025 | Cequa |
| Allergan, INC. | $248.51 | 2019-2022 | |
| Oyster Point Pharma, INC. | $172.81 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $147.32 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $143.76 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $97.20 | 2022-2025 | Miebo, Vyzulta |
| Harrow Eye, LLC | $89.08 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.05 | 2019-2021 | |
| Glaukos Corporation | $63.84 | 2021-2023 | |
| Rxsight INC | $47.88 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $46.35 | 2022-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $42.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $35.11 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $31.64 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $18.68 | 2022 | |
| Thea Pharma INC. | $17.81 | 2023 | |
| Mallinckrodt Hospital Products INC. | $15.83 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.